Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Pain Management Health Center

Font Size

FDA Launches Painkiller Abuse Strategy

Risk-Cutting Plan Covers Extended-Release Opioids; Advisory Panel Had Recommended Including Short-Acting Opioids
WebMD Health News
Reviewed by Laura J. Martin, MD

April 19, 2011 -- Ignoring its expert advisory panel's strong "no" vote, the FDA today launched an education program to cut abuse of long-lasting opioid pain drugs.

The action calls for companies that make long-lasting or extended-release opioid pain drugs to develop a shared plan to educate patients and doctors about how to reduce the risk that the potentially addictive drugs will be abused.

The panel last July voted 24-10 to reject the plan and recommended stronger action that would include short-acting opioids.

"The agency concluded that there is a disproportionate safety problem associated with the extended-release and long-acting opioids which must be addressed, and will incorporate a step-wise approach to focus first on educating prescribers of extended-release and long-acting opioids," the FDA notes in a news release.

The FDA's "risk evaluation and mitigation strategy, or REMS, goes a bit beyond the usual package insert. REMS plans typically include a medication guide and a plan to communicate risk information to both patients and doctors.

In the case of long-acting opioids, the REMS plan is expected to help patients keep their prescription pain drugs out of the hands of potential abusers and to help doctors properly prescribe the drugs.

But for doctors, any education required by the plan will be voluntary.

Doctors will not be required to undergo special training to prescribe opioid pain drugs. However, the FDA is asking Congress to pass legislation that would link mandatory doctor training to getting a Drug Enforcement Administration number that doctors now need to prescribe controlled substances.

The advisory panel strongly supported such legislation.

Drugs covered by the new plan include many well-known brands:

The action covers these generic drugs:

  • Fentanyl extended-release transdermal system
  • Methadone (all versions, as methadone remains in the body for extended periods)
  • Morphine extended-release tablets
  • Oxycodone extended-release tablets

White House Plan to Cut "Epidemic" of Prescription Drug Abuse

The FDA action is part of a multi-agency plan spearheaded by the White House Office of National Drug Control Policy.

The plan calls for collaboration between the departments of Justice, Health and Human Services, Veterans Affairs, and Defense. It seeks to cut prescription drug abuse and to keep prescription drugs from being diverted from patients to recreational users.

It's a big problem. For example, the 2008 National Survey on Drug Use and Health found that only 7% of OxyContin users got the drug from a doctor and 13% bought it from a drug dealer or other stranger. Nearly two-thirds got the drug from a friend or relative.

"The toll our nation’s prescription drug abuse epidemic has taken in communities nationwide is devastating," Gil Kerlikowske, director of the White House Office of National Drug Control Policy, says in a news release.

Today on WebMD

pain in brain and nerves
Top causes and how to find relief.
knee exercise
8 exercises for less knee pain.
acupuncture needles in woman's back
How it helps arthritis, migraines, and dental pain.
chronic pain
Get personalized tips to reduce discomfort.
illustration of nerves in hand
lumbar spine
Woman opening window
Man holding handful of pills
Woman shopping for vegetables
Sore feet with high heel shoes
acupuncture needles in woman's back
man with a migraine